Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine ORR, lasting at least 4 months, with brentuximab vedotin in patients with CD30+ MF or pcALCL compared to that achieved with therapy in the control arm
Critère d'inclusion
- CD30-Positive Cutaneous T-Cell Lymphoma